Home Injectables REVANCE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)

REVANCE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)

0
REVANCE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)

[ad_1]

ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

At the Company’s 2022 annual meeting of stockholders held on May 4, 2022, the
stockholders voted on the three proposals listed below. The proposals are
described in detail in the Company’s definitive proxy statement for the 2022
annual meeting (the “2022 Proxy Statement”), filed with the Securities and
Exchange Commission
on March 24, 2022. The results of the matters voted upon at
the meeting were:

1.Each of the Class II nominees of the Company’s Board of Directors (the
“Board”) were elected to hold office until the Company’s 2025 annual meeting of
stockholders, as follows: Mark J. Foley: 36,119,897 shares of common stock voted
for and 10,379,102 shares of common stock withheld; Christian W. Nolet:
34,035,661 shares of common stock voted for and 12,463,338 shares of common
stock withheld, and Philip J. Vickers: 35,991,502 shares of common stock voted
for and 10,507,497 shares of common stock withheld. There were a total of
8,744,469 broker non-votes for the election of the Class II nominees. The terms
of office of the Class III directors, Jill Beraud and Carey O’Connor Kolaja,
continue until the Company’s 2023 annual meeting of stockholders. The terms of
office of the Class I directors, Angus C. Russell, Julian S. Gangolli and Olivia
C. Ware
continue until the Company’s 2024 annual meeting of stockholders.

2.The stockholders ratified the selection by the Audit Committee of
PricewaterhouseCoopers LLP
as the independent registered public accounting firm
of the Company for its fiscal year ending December 31, 2022, as follows:
55,040,277 shares of common stock voted for, 144,131 shares of common stock
voted against, 59,060 shares of common stock abstaining and no broker non-votes.

3.The stockholders approved, on an advisory basis, the compensation of the
Company’s named executive officers as disclosed in the 2022 Proxy Statement, as
follows: 36,151,026 shares of common stock voted for, 10,270,358 shares of
common stock voted against, 77,615 shares of common stock abstaining and
8,744,469 broker non-votes.

——————————————————————————–

© Edgar Online, source Glimpses

[ad_2]

Source link